Skip to content
OpenCapital
Get started

Haemonetics HAE US — Revenue

Other geography segments

United States
$248.29M—
Japan
$16.11M—
JP
$15.55M—

Similar metrics at other companies

Merit Medical Systems logo
MMSIUS — Revenue
$226.52M+6.1%
PTC Therapeutics logo
PTCTUS — Revenue
$136.52M+186%
NTS
NTSKUS — Revenue
$88.7M+26.2%
Novanta logo
NOVTUS — Revenue
$122.01M-1.3%
Lantheus Holdings logo
LNTHUS — Revenue
$354.43M-0.9%
Seaboard logo
SEBUS — Revenue
$535.5M+1.6%

Other financials

Income statement

See full
Revenue$346.4M+4.8%
Gross profit$198.2M+2.7%
Operating income$67.4M+14.2%
Net income$44.7M+19.3%
EPS (diluted)$0.95+28.4%

Balance sheet

See full
Cash & equivalents$245.4M-20.0%
Total debt$1.3B-0.7%
Total equity$796.3M-3.0%
Total assets$2.4B-2.2%

Cash flow

See full
Operating cash flow$70.9M-39.1%
CapEx$17.7M+12.9%
Free cash flow$53.3M-47.2%

Valuation

See full
Market cap$3.37B-18.0%
Enterprise value$4.4B-12.5%
P/S2.5×-0.5×

Profitability

See full
Gross margin59%+4.0pp
Operating margin19%+5.9pp
Net margin13.3%+3.8pp
FCF margin19.5%+9.1pp

Returns & leverage

See full
Return on equity19.3%+5.2pp
Debt / equity1.6×0.0×
Current ratio3×+1.3×

Where this comes from

Reported directly by Haemonetics in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Haemonetics’s 10-Q, filed February 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Haemonetics's us — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Haemonetics's US — revenue?
Haemonetics (HAE) reported US — revenue of $247.71M in Q4 2025.
How has Haemonetics's US — revenue changed year-over-year?
Haemonetics's US — revenue decreased by 3.9% year-over-year, from $257.67M to $247.71M.
What does US — revenue mean?
This metric represents the total net sales generated from products and services provided to customers located within the United States, excluding any sales-related taxes collected on behalf of government authorities. It serves as a primary indicator of the company's market penetration and commercial performance within the domestic healthcare sector. Tracking this revenue stream helps investors assess the company's ability to capitalize on regional demand for blood and plasma collection technologies and hospital-based medical solutions.